LP Boulet, KR Chapman, J Cote, S Kalra, R Bhagat, VA Swystun, M Laviolette, LD Cleland, F Deschesnes, JQ Su, A DeVault, RB Fick Jr and DW Cockcroft
Centre de Pneumologie, Hopital Laval, Sainte-Foy, Quebec, Canada.

Inhaled allergens, acting through IgE-dependent mechanisms, are important triggers of asthma symptoms and inducers of airway hyperresponsiveness and airway inflammation. The effect of anti-IgE recombinant humanized monoclonal antibody-E25 (rhuMAb-E25) on the provocation concentration of allergen causing a 15% fall in FEV1 (allergen PC15) during the allergen-induced early asthmatic response (EAR) was assessed in a multicenter, randomized, double-blind, parallel group study. Ten of 11 allergic asthmatic subjects randomized to receive intravenous rhuMAb-E25, 2 mg/kg on study day 0 and 1 mg/kg on Days 7, 14, 28, 42, 56, and 70 completed the study; nine received intravenous placebo. The allergen PC15 was measured on Days -1, 27, 55, and 77 and methacholine PC20 on Days -2, 42, and 76. rhuMAb-25 was well tolerated and only one patient (active group) was withdrawn because of a generalized urticarial rash after the first dose. Compared with baseline values (Day -1), the median allergen PC15 on Days 27, 55, and 77 were increased by 2.3, 2.2, and 2.7 doubling doses (delta log PC15/0.3) respectively with rhuMAb-E25 and -0.3, +0.1, and -0.8 doubling doses with placebo (p < or = 0.002). Methacholine PC20 improved slightly after rhuMAb-E25, this change becoming statistically significant on Day 76 (p < 0.05); no change was observed in the placebo group. Mean serum-free IgE fell by 89% after rhuMAb-E25 while there was no significant change after placebo. The inhibitory effects of rhuMAb- E25 on allergen-induced EAR suggest that it may be an effective, novel antiallergic treatment for asthma.

This article has been cited by other articles:

				Y. L. Kuo and C. J. Lai Ovalbumin sensitizes vagal pulmonary C-fiber afferents in Brown Norway rats J Appl Physiol, August 1, 2008; 105(2): 611 - 620. [Abstract] [Full Text] [PDF]

				E. Hamelmann The rationale for treating allergic asthma with anti-IgE Eur. Respir. Rev., September 1, 2007; 16(104): 61 - 66. [Abstract] [Full Text] [PDF]

				A. D. Kraneveld, M. Kool, A. H. van Houwelingen, P. Roholl, A. Solomon, D. S. Postma, F. P. Nijkamp, and F. A. Redegeld From The Cover: Elicitation of allergic asthma by immunoglobulin free light chains PNAS, February 1, 2005; 102(5): 1578 - 1583. [Abstract] [Full Text] [PDF]

				R. Djukanovic, S. J. Wilson, M. Kraft, N. N. Jarjour, M. Steel, K. F. Chung, W. Bao, A. Fowler-Taylor, J. Matthews, W. W. Busse, et al. Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 583 - 593. [Abstract] [Full Text] [PDF]

				L. A Davis Omalizumab: A Novel Therapy for Allergic Asthma Ann. Pharmacother., July 1, 2004; 38(7): 1236 - 1242. [Abstract] [Full Text] [PDF]

				D. C. Grootendorst and K. F. Rabe Mechanisms of Bronchial Hyperreactivity in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2004; 1(2): 77 - 87. [Abstract] [Full Text] [PDF]

				P. E. Silkoff, F. A. Romero, N. Gupta, R. G. Townley, and H. Milgrom Exhaled Nitric Oxide in Children With Asthma Receiving Xolair (Omalizumab), a Monoclonal Anti-Immunoglobulin E Antibody Pediatrics, April 1, 2004; 113(4): e308 - e312. [Abstract] [Full Text] [PDF]

				G. Hanf, O. Noga, A. O'Connor, and G. Kunkel Omalizumab inhibits allergen challenge-induced nasal response Eur. Respir. J., March 1, 2004; 23(3): 414 - 419. [Abstract] [Full Text] [PDF]

				S. Sehra, G. Pynaert, K. Tournoy, A. Haegeman, P. Matthys, Y. Tagawa, R. Pauwels, and J. Grooten Airway IgG Counteracts Specific and Bystander Allergen-Triggered Pulmonary Inflammation by a Mechanism Dependent on Fc{gamma}R and IFN-{gamma} J. Immunol., August 15, 2003; 171(4): 2080 - 2089. [Abstract] [Full Text] [PDF]

				M. J. Holtzman Drug Development for Asthma Am. J. Respir. Cell Mol. Biol., August 1, 2003; 29(2): 163 - 171. [Abstract] [Full Text] [PDF]

				H. A. Boushey New and Exploratory Therapies for Asthma Chest, March 1, 2003; 123(2007): 439S - 445S. [Full Text] [PDF]

				H Milgrom Is there a role for treatment of asthma with omalizumab? Arch. Dis. Child., January 1, 2003; 88(1): 71 - 74. [Abstract] [Full Text] [PDF]

				R. Buhl, G. Hanf, M. Soler, G. Bensch, J. Wolfe, F. Everhard, K. Champain, H. Fox, and J. Thirlwell The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma Eur. Respir. J., November 1, 2002; 20(5): 1088 - 1094. [Abstract] [Full Text] [PDF]

				R. Buhl, M. Soler, J. Matz, R. Townley, J. O'Brien, O. Noga, K. Champain, H. Fox, J. Thirlwell, and G. Della Cioppa Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Eur. Respir. J., July 1, 2002; 20(1): 73 - 78. [Abstract] [Full Text] [PDF]

				J Douwes, P Gibson, J Pekkanen, and N Pearce Non-eosinophilic asthma: importance and possible mechanisms Thorax, July 1, 2002; 57(7): 643 - 648. [Abstract] [Full Text] [PDF]

				J. R. Crosby, G. Cieslewicz, M. Borchers, E. Hines, P. Carrigan, J. J. Lee, and N. A. Lee Early Phase Bronchoconstriction in the Mouse Requires Allergen-Specific IgG J. Immunol., April 15, 2002; 168(8): 4050 - 4054. [Abstract] [Full Text] [PDF]

				T. B. Casale, J. Condemi, C. LaForce, A. Nayak, M. Rowe, M. Watrous, M. McAlary, A. Fowler-Taylor, A. Racine, N. Gupta, et al. Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis: A Randomized Controlled Trial JAMA, December 19, 2001; 286(23): 2956 - 2967. [Abstract] [Full Text] [PDF]

				E. S. SCHULMAN Development of a Monoclonal Anti-Immunoglobulin E Antibody (Omalizumab) for the Treatment of Allergic Respiratory Disorders Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): S6 - 11. [Abstract] [Full Text] [PDF]

				W. W. BUSSE Anti-Immunoglobulin E (Omalizumab) Therapy in Allergic Asthma Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): S12 - 17. [Abstract] [Full Text] [PDF]

				M. Soler, J. Matz, R. Townley, R. Buhl, J. O'Brien, H. Fox, J. Thirlwell, N. Gupta, and G. Della Cioppa The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Eur. Respir. J., August 1, 2001; 18(2): 254 - 261. [Abstract] [Full Text] [PDF]

				H. Milgrom, W. Berger, A. Nayak, N. Gupta, S. Pollard, M. McAlary, A. F. Taylor, and P. Rohane Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab) Pediatrics, August 1, 2001; 108 (2): e36 - e36. [Abstract] [Full Text] [PDF]

				P. G. Woodruff and J. V. Fahy Asthma: Prevalence, Pathogenesis, and Prospects for Novel Therapies JAMA, July 25, 2001; 286(4): 395 - 398. [Full Text] [PDF]

				W. W. Busse and R. F. Lemanske Asthma N. Engl. J. Med., February 1, 2001; 344(5): 350 - 362. [Full Text] [PDF]

				H. Milgrom, R. B. Fick, J. Q. Su, J. D. Reimann, R. K. Bush, M. L. Watrous, W. J. Metzger, and The rhuMAb-E25 Study Group Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody N. Engl. J. Med., December 23, 1999; 341(26): 1966 - 1973. [Abstract] [Full Text] [PDF]

				P. J. Barnes Anti-IgE Antibody Therapy for Asthma N. Engl. J. Med., December 23, 1999; 341(26): 2006 - 2008. [Full Text]

				J. V. FAHY, D. W. COCKCROFT, L.-P. BOULET, H. H. WONG, F. DESCHESNES, E. E. DAVIS, J. RUPPEL, J. Q. SU, and D. C. ADELMAN Effect of Aerosolized Anti-IgE (E25) on Airway Responses to Inhaled Allergen in Asthmatic Subjects Am. J. Respir. Crit. Care Med., September 1, 1999; 160(3): 1023 - 1027. [Abstract] [Full Text]

				S. Sur, J. S. Wild, B. K. Choudhury, N. Sur, R. Alam, and D. M. Klinman Long Term Prevention of Allergic Lung Inflammation in a Mouse Model of Asthma by CpG Oligodeoxynucleotides J. Immunol., May 15, 1999; 162(10): 6284 - 6293. [Abstract] [Full Text] [PDF]

				S. S. Saini, D. W. MacGlashan Jr., S. A. Sterbinsky, A. Togias, D. C. Adelman, L. M. Lichtenstein, and B. S. Bochner Down-Regulation of Human Basophil IgE and FC{epsilon}RI{alpha} Surface Densities and Mediator Release by Anti-IgE-Infusions Is Reversible In Vitro and In Vivo J. Immunol., May 1, 1999; 162(9): 5624 - 5630. [Abstract] [Full Text] [PDF]

				K. F. RABE Mechanisms of Immune Sensitization of Human Bronchus Am. J. Respir. Crit. Care Med., November 1, 1998; 158(2007): S161 - S170. [Abstract] [Full Text] [PDF]

				A. J. M. Van Oosterhout, B. Van Esch, G. Hofman, C. L. Hofstra, I. Van Ark, F. P. Nijkamp, M. L. Kapsenberg, H. F. J. Savelkoul, and F. R. Weller Allergen Immunotherapy Inhibits Airway Eosinophilia and Hyperresponsiveness Associated with Decreased IL-4 Production by Lymphocytes in a Murine Model of Allergic Asthma Am. J. Respir. Cell Mol. Biol., October 1, 1998; 19(4): 622 - 628. [Abstract] [Full Text]